
Therapeutic advances in the last 3 decades in bladder cancer were very limited. The 21th century will be more promising with the advent of immunotherapies, with at the top of the list the immune-checkpoint inhibitors. The promising results of the early trials let us hope that these new therapies will soon enroll in the therapeutic landscape of urothelial carcinoma. This article reviews the clinical data of ongoing immunotherapeutic trials (checkpoint inhibitors, vaccine, cytokine) and also the association of the therapies with chemotherapy, antiangiogenics and radiotherapy.